Advances in adjuvant therapy of colon Cancer

Surgical resection is the primary curative modality for colon cancer but outcomes are variable and dependent on risk of recurrence. Currently, stage and a variety of clinicopathologic risk factors are used to estimate recurrence risk. Adjuvant chemotherapy is recommended for most patients with stage III disease and high-risk patients with stage II disease to reduce the risk of recurrence and improve outcomes. Fluoropyrimidines with and without oxaliplatin have proven benefit, but there is no effect of other agents including irinotecan, anti-vascular endothelial growth factor, or anti-epidermal growth factor agents in this setting.
Source: Seminars in Colon and Rectal Surgery - Category: Gastroenterology Authors: Source Type: research